New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:38 EDTCPXXCelator announces data, recommendation to continue CPX-351 Phase 3 study
Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:06 EDTCPXXCelator Pharmaceuticals granted European patent on nanoparticle technology
Subscribe for More Information
December 15, 2014
10:20 EDTCPXXCelator participates in lunch meeting with Philadelphia Securities Association
Subscribe for More Information
December 10, 2014
08:33 EDTCPXXCelator Pharmaceuticals' CPX-351 leukemia candidate shows positive results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use